No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 18
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T19:59:26.780Z. Latest historical point 2023-03-31.
The latest delayed quote for Tevogen Bio Holdings Inc. (TVGN) stock was $6.73 as of Oct 6, 2026, 3:52 PM EDT, up 1.97% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -80.3% · 3-year avg -77.0%/yr
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology.
Biotechnology · Warren, NJ
Next Earnings Date
Nov 13, 2026
38 days away
EPS Estimate
-2.56
Revenue Est.
N/A
Last Quarter Results
EPS
$-7.96
vs Estimate
$-1.50
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1TVGN | $28.03M | $6.73 | +1.97% | -80.26% | N/A | N/A | N/A |
| 2MCRB | $28.03M | $2.90 | +1.58% | -86.03% | -53.37% | -35.85% | vs TVGN |
| 3ATYR | $27.79M | $0.28 | -2.28% | -62.41% | N/A | N/A | vs TVGN |
| 4ONMD | $28.59M | $5.02 | -1.76% | -50.22% | -44.89% | N/A | vs TVGN |
| 5CNTX | $29.32M | $0.32 | -5.17% | -69.24% | N/A | N/A | vs TVGN |
| 6QUCY | $29.60M | $1.30 | -3.70% | N/A | N/A | N/A | vs TVGN |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$6.73
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-2.56 | $-2.56 | $-2.56 | 1 |
| Quarter ending Dec 2026 | $-2.41 | $-2.41 | $-2.41 | 1 |
| Quarter ending Mar 2027 | $-3.38 | $-3.38 | $-3.38 | 1 |
| Quarter ending Jun 2027 | $-3.25 | $-3.25 | $-3.25 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-10.14 | $-10.14 | $-10.14 | 1 |
| FY 2027 | $-13.01 | $-13.01 | $-13.01 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $502.27M | $502.27M | $502.27M | 1 |
